98 related articles for article (PubMed ID: 23323945)
1. Pharmacogenetic analysis in the treatment of Hodgkin lymphoma.
Altés A; Paré L; Esquirol A; Xicoy B; Rámila E; Vicente L; López R; Orriols J; Vall-llovera F; Sánchez-González B; del Río E; Sureda A; Páez D; Baiget M
Leuk Lymphoma; 2013 Aug; 54(8):1706-12. PubMed ID: 23323945
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.
Ribrag V; Koscielny S; Casasnovas O; Cazeneuve C; Brice P; Morschhauser F; Gabarre J; Stamatoullas A; Lenoir G; Salles G;
Blood; 2009 Apr; 113(14):3307-13. PubMed ID: 18768784
[TBL] [Abstract][Full Text] [Related]
3. Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial.
Morabito F; Hohaus S; Mammi C; Marcheselli L; Gentile M; Merli F; Montanini A; Stelitano C; La Sala A; Scalone R; Voso MT; Luminari S; Iannitto E; Gobbi P; Federico M
Leuk Lymphoma; 2012 Mar; 53(3):406-10. PubMed ID: 21916526
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma.
Lourenço GJ; Lorand-Metze I; Delamain MT; Miranda EC; Kameo R; Metze K; Lima CS
Leuk Lymphoma; 2010 Dec; 51(12):2215-21. PubMed ID: 20977336
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
7. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy.
Alonso-Álvarez S; Vidriales MB; Caballero MD; Blanco O; Puig N; Martin A; Peñarrubia MJ; Zato E; Galende J; Bárez A; Alcoceba M; Orfão A; González M; García-Sanz R
Leuk Lymphoma; 2017 May; 58(5):1144-1152. PubMed ID: 27733075
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.
Kamran SC; Jacene HA; Chen YH; Mauch PM; Ng AK
Leuk Lymphoma; 2018 Jun; 59(6):1384-1390. PubMed ID: 28937297
[TBL] [Abstract][Full Text] [Related]
9. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
10. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
11. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma.
Yri OE; Ekstrøm PO; Hilden V; Gaudernack G; Liestøl K; Smeland EB; Holte H
Leuk Lymphoma; 2012 Oct; 53(10):1934-44. PubMed ID: 22475179
[TBL] [Abstract][Full Text] [Related]
13. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
[TBL] [Abstract][Full Text] [Related]
15. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of glutathione S-transferase Mu 1, glutathione S-transferase theta 1 and glutathione S-transferase Pi 1 genes in Hodgkin's lymphoma susceptibility and progression.
Lourenço GJ; Néri IA; Sforni VC; Kameo R; Lorand-Metze I; Lima CS
Leuk Lymphoma; 2009 Jun; 50(6):1005-9. PubMed ID: 19391035
[TBL] [Abstract][Full Text] [Related]
17. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
19. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation.
Gunther JR; Fanale MA; Reddy JP; Akhtari M; Smith GL; Pinnix CC; Milgrom SA; Yehia ZA; Allen PK; Osborne EM; Mawlawi O; Dabaja BS
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):110-8. PubMed ID: 27325479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
